The tiny clinking vials supervised by silent PPE-wearing technicians belie the excitement inside the world's largest vaccine manufacturer, the Serum Institute of India, a major player in the fight against coronavirus.
Image Credit: AFP
2 of 20
The firm, founded in 1966 in the western city of Pune, is producing millions of doses of the Covishield vaccine, developed by AstraZeneca and Oxford University, for India and much of the developing world.
Image Credit: AFP
3 of 20
Unlike the rival Pfizer-BioNTech vaccine, Covishield can be stored and transported using standard refrigeration. It is also significantly cheaper than the vaccines developed by Pfizer or the US firm Moderna, making it better suited for countries with poorer populations and rusty infrastructure.
Image Credit: AFP
4 of 20
An employee in protective gear works on an assembly line for manufacturing vials of Covishield, AstraZeneca-Oxford's Covid-19 coronavirus vaccine at India's Serum Institute in Pune.
Image Credit: AFP
5 of 20
Even before the pandemic, the Indian firm was a world leader in vaccines, producing 1.5 billion doses a year and inoculating two out of three children in 170 countries against diseases such as polio, mumps, meningitis and measles.
Image Credit: AFP
6 of 20
Its journey kicked off on a stud farm, where the firm's owners, the Poonawalla family, began breeding horses in 1946, before a conversation with a vet sparked the realisation that anti-toxin serum extracted from the animals could be used to make vaccines.
Image Credit: AFP
7 of 20
The Serum Institute soon became a market leader thanks to its cheap and effective drugs, which were eagerly sought after by price-conscious governments and consumers, prompting the company to expand at a dizzying rate.
Image Credit: AFP
8 of 20
Adar Poonawalla (pictured), its 40-year-old CEO, has spent nearly a billion dollars in recent years enlarging and improving the sprawling Pune campus.
Image Credit: Supplied
9 of 20
As a result, when the coronavirus pandemic began to sweep across the world, the company, which recorded annual revenues of over $800 million in 2019-20 and is debt-free, was in pole position to reap the rewards.
Image Credit: AFP
10 of 20
A general view of the Serum Institute campus in Pune.
Image Credit: AFP
11 of 20
The palm-fringed Pune campus, whose grounds boast horse-shaped topiaries in a playful nod to the firm's origins, is home to several buildings where vaccines are manufactured and scrutinised for quality before being deposited into sterilised vials and stored for delivery.
Image Credit: AFP
12 of 20
With Poonawalla vowing to reserve 50 percent of Covishield stocks for the Indian market, New Delhi, which intends to immunise 300 million people by July, is engaging in a bout of vaccine diplomacy, planning to supply 20 million doses to its South Asian neighbours.
Image Credit: AFP
13 of 20
The Serum Institute also plans to supply 200 million doses to Covax, a World Health Organization-backed effort to procure and distribute inoculations to poor countries.
Image Credit: AFP
14 of 20
If all this sounds overwhelming, the firm's bosses are not worried. "We are used to these kinds of pressures because even in the past there were situations when we were required to step up the production to meet individual countries' requirements," Suresh Jadhav, Serum Institute's executive director, told AFP.
Image Credit: AFP
15 of 20
Even a deadly fire at an under-construction building this week failed to dent confidence, with Poonawalla promptly tweeting that "there would be no loss of #COVISHIELD production due to multiple production buildings that I had kept in reserve to deal with such contingencies".
Image Credit: AFP
16 of 20
Vials of Covishield, AstraZeneca-Oxford's Covid-19 coronavirus vaccine are pictured inside a lab.
Image Credit: AFP
17 of 20
An employee in protective gear pushes a trolley inside a lab.
Image Credit: AFP
18 of 20
A worker prepares to stack boxes containing vials of Covishield, inside a cold storage room.
Image Credit: AFP
19 of 20
Employees prepare themselves before getting inside a lab.
Image Credit: AFP
20 of 20
Vials of Covishield, AstraZeneca-Oxford's Covid-19 coronavirus vaccine are pictured inside a lab.
Image Credit: AFP
This website stores cookies on your computer. These cookies are used to improve your experience and provide more personalized service to you.
Both on your website and other media. To find out more about the cookies and data we use, please check out our Privacy Policy.
